Loss-Making Ikonisys S.A. (EPA:ALIKO) Expected To Breakeven In The Medium-Term

Ikonisys S.A. (EPA:ALIKO) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. The €24m market-cap company announced a latest loss of €3.2m on 31 December 2024 for its most recent financial year result. Many investors are wondering about the rate at which Ikonisys will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Ikonisys is bordering on breakeven, according to some French Medical Equipment analysts. They expect the company to post a final loss in 2026, before turning a profit of €1.0m in 2027. The company is therefore projected to breakeven around 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 76% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Given this is a high-level overview, we won’t go into details of Ikonisys' upcoming projects, but, take into account that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

Check out our latest analysis for Ikonisys

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 28% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Ikonisys, so if you are interested in understanding the company at a deeper level, take a look at Ikonisys' company page on Simply Wall St. We've also put together a list of important factors you should further research:

1. Valuation: What is Ikonisys worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Ikonisys is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Ikonisys’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.